Shares of Lupin Ltd were trading in the green and 2% higher on 10 April after the company announced launching its first generic version of Oracea (doxycycline capsules) in the US.

In its regulatory filing, the company said, “The company has announced the launch of the first generic version of Oracea (doxycycline capsules, 40 mg), in the United States, after having received an approval from the United States Food and Drug Administration (USFDA).”

The doxycycline capsules are used for the treatment of inflammatory lesions of rosacea in adult patients. According to the IQVIA MAT Data, the Oracea (Doxycycline capsules) have an estimated annual sales of $128 million in the US.

Earlier on 21 March, the company initiated the recall of 26,352 bottles of Rifampin capsules in the US market as it was identified to be a sub-potent drug.

The Rifampin capsule is used in the treatment of all forms of tuberculosis. It was manufactured at the company’s Aurangabad plant and sold by the US arm of Lupin.

Furthermore, in March, the Aurangabad facility of the company was inspected by the US regulator between 6 March and 15 March, following which the unit received Form 483 with one observation.

At 12:50 pm, the shares of Lupin were trading 0.63% higher at Rs 1,615.90 on NSE.